CAJ | 학술논문

目的探讨RRM1基因表达与晚期非小细胞肺癌含吉西他滨化疗方案疗效的关系.方法有40例接受含吉西他滨方案化疗晚期非小细胞肺癌患者入组,采用分支DNA-液相芯片技术检测RRM1mRNA表达的水平,预测吉西他滨在晚期肺癌中的化疗疗效.结果 RRM1低表达者23例(57.5％),高表达者17例(42.5％),低表达与高表达患者的化疗有效率、疾病进展时间分别为78.2％、12.4个月和35.2％、8.2个月,两组比较差异有统计学意义(P＜0.05).结论 RRM1基因表达水平可作为预测晚期非小细胞肺癌对含吉西他滨化疗方案的指标之一.
목적 탐토RRM1기인표체여만기비소세포폐암함길서타빈화료방안료효적관계.방법 유40례접수함길서타빈방안화료만기비소세포폐암환자입조,채용분지DNA-액상심편기술검측RRM1mRNA표체적수평,예측길서타빈재만기폐암중적화료료효.결과 RRM1저표체자23례(57.5％),고표체자17례(42.5％),저표체여고표체환자적화료유효솔、질병진전시간분별위78.2％、12.4개월화35.2％、8.2개월,량조비교차이유통계학의의(P＜0.05).결론 RRM1기인표체수평가작위예측만기비소세포폐암대함길서타빈화료방안적지표지일.
Objective To investigate the relationship between genetic polymorphisms of RRM 1 and survival of patients with advanced non-small cell lung cancer(NSCLC) treated with gemcitabine based chemotherapy.Methods 40 cases treated with gemcitabine chemotherapy in patients with advanced non-small cell lung cancer,the branch DNA-liquid chip detection of RRM1 mRNA expression level,curative effect of gemcitabine in advanced lung cancer prediction.Results 23 patients with low expression of RRM1 (57.5％),high expression in 17 cases (42.5％),and low expression in patients with high expression of chemotherapy efficiency,time to disease progression was 78.2％,35.2％,12.4 months and 8.2 months,with a significant difference between two groups (P＜0.05).Conclusion The expression of RRM1 gene could be used to predict the chemotherapy index of advanced non-small cell cancer with gemcitabine platinum.